UK's Regulatory Agency Takes Action on LinkedIn Pharma Marketing
February 15, 2016
MHRA has reprimanded a dermatology company after receiving an anonymous complaint about promotional material for a prescription drug shared on the social networking site LinkedIn.
The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) said it has reprimanded a dermatology company after receiving an anonymous complaint about promotional material for a prescription drug shared on the social networking site LinkedIn.
MHRA said it upheld the complaint as the UK, unlike the US, does not allow prescription-only medicines to be promoted to the public though it does allow advertisements for over-the-counter medicines, according to guidance.
Switzerland-based company assured MHRA that the material was a single employee’s error of judgement outside of the company’s knowledge or authority. The company provided details of remedial action to ensure all of its staff are aware of company policy on the use of social media.
MHRA also announced that 10 UK clinics advertising botulinum toxin products amended their advertising to ensure prescription drugs are not advertised to the public.
Last February, MHRA released a report on advertising complaints, noting that there were 193 complaints about online advertisements in 2014, down from 237 in 2013.
Regulators and the Web
Regulators seem to be looking more consistently at social media to find pharmaceutical marketing practices that do not meet their standards. The US Food and Drug Administration previously issued a warning letter for comments made on Facebook, Twitter and Pinterest. FDA has been embroiled in a debate with industry and the courts over what should be considered free speech and what should be considered off-label marketing, with at least one expert thinking the issue could head to the US Supreme Court.
MHRA also collaborated with the European Monitoring Centre for Drugs and Drug Addiction in a new report on the Internet and drugs (illicit and prescription). The report notes that the legal position surrounding the online supply of medicines varies across the EU, with some countries, such as the UK and Germany, allowing all classes of medicines (prescription and OTC medicines) to be sold online, while others allow only OTC medicines, and some, such as Italy, prohibit the supply of all medicines online.
As far as advertising online in the EU, the report notes that it “is not permitted anywhere” and any Web advertising of prescription medicines is in breach of legislative requirements and action can be taken to remove the website.RAPS